Company profile for Seqirus

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Seqirus, formerly bioCSL, manufactures and in-licenses, markets and distributes vaccines with particular focus on vaccines for the prevention and treatment of serious disease. We operate one of the world’s largest influenza vaccine manufacturing facilities and supply seasonal influenza vaccines to Australia and global markets. In July 2015, bioCSL and the influenza vaccines of Novartis joined forces to create Seqirus, now th...
Seqirus, formerly bioCSL, manufactures and in-licenses, markets and distributes vaccines with particular focus on vaccines for the prevention and treatment of serious disease. We operate one of the world’s largest influenza vaccine manufacturing facilities and supply seasonal influenza vaccines to Australia and global markets. In July 2015, bioCSL and the influenza vaccines of Novartis joined forces to create Seqirus, now the second largest influenza vaccine company in the world.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Australia
Address
Address
63 Poplar Road Parkville Victoria 3052
Telephone
Telephone
+61 3 9389 2000
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/recent-rwe-data-show-cell-based-influenza-vaccines-offer-20-greater-protection-in-the-prevention-of-test-confirmed-influenza-in-pediatric-and-adult-populations-relative-to-standard-egg-based-influenza-vaccines-302590073.html

PR NEWSWIRE
21 Oct 2025

https://www.prnewswire.com/news-releases/new-data-presented-at-idweek-2024-show-adjuvanted-and-high-dose-influenza-vaccines-are-comparable-in-protecting-adults-65-years-of-age-and-older-against-seasonal-influenza-302280334.html

PR NEWSWIRE
18 Oct 2024

https://www.prnewswire.com/news-releases/csl-seqirus-presents-data-at-idweek-2024-highlighting-the-urgent-need-to-increase-influenza-vaccination-rates-and-the-benefits-of-cell-based-influenza-vaccines-302277865.html

PR NEWSWIRE
16 Oct 2024

https://www.fiercepharma.com/pharma/eu-bulks-pre-pandemic-vaccine-stockpile-four-year-csl-seqirus-contract-40-million-bird-flu

FIERCE PHARMA
12 Jun 2024

https://www.prnewswire.com/news-releases/csl-seqirus-a-proud-champion-of-pandemic-preparedness-announces-us-government-award-in-response-to-avian-influenza-302159392.html

PR NEWSWIRE
30 May 2024

https://www.prnewswire.com/news-releases/recently-published-real-world-evidence-study-shows-effectiveness-of-cell-based-quadrivalent-influenza-vaccine-over-three-seasons-302134540.html

PR NEWSWIRE
02 May 2024

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty